摘要
目的比较国产雷帕霉素药物洗脱支架（FireBird，微创公司）和进口帕霉素药物洗脱支架（Cypher，强生公司）治疗冠状动脉原发病变的安全性和临床疗效。方法2003年5月至2005年7月，288例冠状动脉原发病变患者接受雷帕霉素药物洗脱支架治疗，167例接受了FireBird支架，121例接受了Cypher支架，随访6—32个月.结果FireBird组和Cypher组各对148例（88．6％）和106例（87．6％）进行了临床随访，FireBird组总的临床事件发生率9．46％，Cypher组总的临床事件发生率7．55％，两组间差异无统计学意义。结论国产和进口雷帕霉素洗脱支架具有相似的疗效及安全性.
Objective To study and contrast the clinical application efficacy of rapamycin eluting stent between Chinese making and imported. Methods From May 2003 to July 2005,167 patients underwent coronary artery stenting with FireBird （FireBird group）, 121 patients with Cypher （Cypher group）. The patients were followed up for 6 -32 months. Results ①Baseline demographics： 148（88.6% ） and 106（87.6% ） patients were separately followed up in Fire Bird and Cypher group. There were no differences in clinical data between two group. ②Clinical end - point events：the overall adverse sevent rate was 9.46% in FireBird group and 7. 55% in Cypher group. Conclusion The FireBird is safe and effective in treating de novo native coronary artery lesions with similar outcomes of the Cypher.
出处
《中原医刊》
2006年第13期4-6,共3页
Central Plains Medical Journal
关键词
冠心病
雷帕霉素
洗脱支架
国产
进口
Coronary artery disease
Raparaycin
Eluting stent
Made＇in China
Import
